Shortage changes
New and resolved shortages
In the eight weeks to 22 Sept 2026, the FDA first posted 67 shortage records and marked 7 resolved. A record is one manufacturer and presentation, so one drug can carry several.
16 Sept 2026 to 22 Sept 2026
| Change | Drug | Manufacturer | Status now | Records | FDA date |
|---|---|---|---|---|---|
| First posted | Arsenic Trioxide Injection | Fresenius Kabi USA, LLC | To Be Discontinued | 1 | 21 Sept 2026 |
| First posted | Rivaroxaban For Suspension | Janssen Pharmaceuticals | To Be Discontinued | 1 | 18 Sept 2026 |
| First posted | Rivastigmine Film, Extended Release | Mylan Pharmaceuticals Inc., a Viatris Company | To Be Discontinued | 1 | 18 Sept 2026 |
| First posted | Melphalan Hydrochloride Injection | Fresenius Kabi USA, LLC | To Be Discontinued | 1 | 16 Sept 2026 |
| First posted | Mesalamine Capsule, Extended Release | Takeda Pharmaceuticals USA Inc. | To Be Discontinued | 2 | 16 Sept 2026 |
9 Sept 2026 to 15 Sept 2026
| Change | Drug | Manufacturer | Status now | Records | FDA date |
|---|---|---|---|---|---|
| First posted | Cisatracurium Besylate Injection | Hospira, Inc., a Pfizer Company | To Be Discontinued | 1 | 11 Sept 2026 |
| First posted | Micafungin Sodium Injection | Par Health, USA LLC | To Be Discontinued | 2 | 11 Sept 2026 |
| First posted | Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride Solution | Fresenius Medical Care North America | To Be Discontinued | 1 | 10 Sept 2026 |
| First posted | Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection | Merck Sharp & Dohme LLC | To Be Discontinued | 1 | 9 Sept 2026 |
26 Aug 2026 to 1 Sept 2026
| Change | Drug | Manufacturer | Status now | Records | FDA date |
|---|---|---|---|---|---|
| First posted | Glycerol Phenylbutyrate Oral Liquid | Amgen Inc. | To Be Discontinued | 2 | 1 Sept 2026 |
| First posted | Insulin Glargine-aglr Injection | Eli Lilly and Co. | To Be Discontinued | 1 | 1 Sept 2026 |
| First posted | Insulin Lispro Injection | Eli Lilly and Co. | To Be Discontinued | 1 | 1 Sept 2026 |
| First posted | Insulin Lispro Protamine and Insulin Lispro Injection | Eli Lilly and Co. | To Be Discontinued | 1 | 1 Sept 2026 |
| First posted | Medroxyprogesterone Acetate Tablet | Pfizer Inc. | To Be Discontinued | 2 | 31 Aug 2026 |
| First posted | Metoprolol Succinate Tablet, Extended Release | Teva Pharmaceuticals USA, Inc. | To Be Discontinued | 7 | 31 Aug 2026 |
| First posted | Palovarotene Capsule | Ipsen Biopharmaceuticals, Inc. | To Be Discontinued | 1 | 31 Aug 2026 |
| First posted | Potassium Chloride, Sodium Chloride, Calcium Chloride, and Magnesium Chloride Injection, Solution | Fresenius Kabi USA, LLC | To Be Discontinued | 1 | 31 Aug 2026 |
| Resolved | Albuterol Sulfate Solution | Nephron Pharmaceuticals Corporation; Rising Pharma Holdings, Inc.; Ritedose Pharmaceuticals, LLC | Resolved | 3 | 27 Aug 2026 |
| Resolved | Peginterferon alfa-2a Injection | pharmaand GmbH (pharma&) | Resolved | 2 | 27 Aug 2026 |
| First posted | Pentostatin Injection | Hospira, Inc., a Pfizer Company | Current | 1 | 27 Aug 2026 |
19 Aug 2026 to 25 Aug 2026
| Change | Drug | Manufacturer | Status now | Records | FDA date |
|---|---|---|---|---|---|
| First posted | Mesalamine Capsule, Extended Release | Mylan Pharmaceuticals Inc., a Viatris Company | To Be Discontinued | 1 | 25 Aug 2026 |
| First posted | Disopyramide Phosphate Capsule, Extended Release | Pfizer Inc. | To Be Discontinued | 2 | 24 Aug 2026 |
12 Aug 2026 to 18 Aug 2026
| Change | Drug | Manufacturer | Status now | Records | FDA date |
|---|---|---|---|---|---|
| First posted | Fulvestrant Injection | Fresenius Kabi USA, LLC | To Be Discontinued | 1 | 14 Aug 2026 |
| First posted | Diclofenac Sodium Tablet, Delayed Release | Teva Pharmaceuticals USA, Inc. | To Be Discontinued | 6 | 13 Aug 2026 |
| First posted | Polyethylene glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, and Potassium Chloride Oral Solution | Salix Pharmaceuticals, a division of Bausch Health US, LLC | To Be Discontinued | 1 | 13 Aug 2026 |
5 Aug 2026 to 11 Aug 2026
| Change | Drug | Manufacturer | Status now | Records | FDA date |
|---|---|---|---|---|---|
| First posted | Glyburide Tablet | Sanofi-Aventis U.S. LLC | To Be Discontinued | 4 | 10 Aug 2026 |
| Resolved | Rifapentine Tablet, Film Coated | Sanofi-Aventis U.S. LLC | Resolved | 1 | 6 Aug 2026 |
29 Jul 2026 to 4 Aug 2026
| Change | Drug | Manufacturer | Status now | Records | FDA date |
|---|---|---|---|---|---|
| First posted | Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution | Vantive US Healthcare LLC | To Be Discontinued | 18 | 3 Aug 2026 |
| Resolved | Triamcinolone Acetonide Injection | Harrow Eye, LLC | Resolved | 1 | 31 Jul 2026 |
| First posted | Doxycycline Hyclate Tablet, Delayed Release | Teva Pharmaceuticals USA, Inc. | To Be Discontinued | 2 | 30 Jul 2026 |
| First posted | Glycopyrrolate Injection | Fresenius Kabi USA, LLC | To Be Discontinued | 4 | 30 Jul 2026 |
Provenance
FDA drug shortage database via openFDA, re-read daily. “First posted” uses the FDA’s initial posting date; “Resolved” is a record whose status is Resolved, dated by the FDA’s update date. Records the FDA removes from the feed without marking them resolved do not appear here.